![Sandra Downes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sandra Downes
Corporate Officer/Principal at The University of Manchester
Sandra Downes active positions
Companies | Position | Start | End |
---|---|---|---|
The University of Manchester | Corporate Officer/Principal | 19/11/2009 | - |
Career history of Sandra Downes
Former positions of Sandra Downes
Companies | Position | Start | End |
---|---|---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 19/11/2009 | 17/01/2011 |
Statistics
International
United Kingdom | 2 |
Israel | 2 |
Operational
Corporate Officer/Principal | 2 |
Sectoral
Commercial Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
- Stock Market
- Insiders
- Sandra Downes
- Experience